The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Concerns on Atrophic Gastritis and Neoplasia: Unsafe Perspective

위축성 위염 혹은 위암에 미치는 프로톤펌프억제제의 영향: Unsafe 측면

  • Song , Chang-Seok (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Dong-Il (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 송창석 (성균관대학교 의과대학 강북삼성병원 내과) ;
  • 박동일 (성균관대학교 의과대학 강북삼성병원 내과)
  • Published : 2011.07.01
⟨ Previous Next ⟩

Abstract

Proton-pump inhibitors (PPI) have important roles in the management of acid-related disorders, especially gastro-esophageal reflux disease and peptic ulcer disease. They are considered safe, but some side effects, such as oxyntic cell hyperplasia, glandular cysts, hypergastrinemia and fundic gland polyps, are also reported. Long-term PPI administration in Helicobacter pylori (H. pylori) positive subjects promotes a shift from antral to corpus-predominant gastritis. The shift leads to corpus atrophy eventually that is known predisposing factor of gastric adenocarcinoma. It is recommended that patients being considered for long-term PPI therapy should be tested for H. pylori infection. And if present, H. pylori eradication should be preceded to PPI administration. Also, long-term PPI administration can cause enterochromaffin-like cell hyperplasia. Although the underlying mechanism and pathogenesis are not yet fully understood, it is possible that long-term PPI administration can promote the development of gastric carcinoid tumor. Therefore, to minimize the side effects, it should be used in adequate dose for a precise duration.

Keywords

References

  1. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-944. https://doi.org/10.1053/j.gastro.2008.01.010
  2. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-734. https://doi.org/10.1056/NEJM199803123381105
  3. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-1348. https://doi.org/10.1111/j.1365-2036.2006.03127.x
  4. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(Suppl 1):55-63.
  5. Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology 1993;105:1590-1591.
  6. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-1022. https://doi.org/10.1056/NEJM199604183341603
  7. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401-1406.
  8. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006;55:1538-1544. https://doi.org/10.1136/gut.2005.086579
  9. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35(Suppl 1):42-55.
  10. Dawson R, Manson JM. Omeprazole in oesophageal reflux disease. Lancet 2000;356:1770-1771.
  11. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl 1985;108:53-69.
  12. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885-891. https://doi.org/10.1097/00042737-200308000-00009
  13. El-Zimaity HMT, Gutierrez O, Kim JG, et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 2001;96:666-672. https://doi.org/10.1111/j.1572-0241.2001.03601.x
  14. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
  15. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-691. https://doi.org/10.1016/0016-5085(95)90374-7
  16. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20. https://doi.org/10.1136/gut.53.1.12
  17. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009;104:1642-1649. https://doi.org/10.1038/ajg.2009.172
  18. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319-326. https://doi.org/10.1053/gast.1999.0029900319
  19. Pounder RE, Williams MP. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:238-239. https://doi.org/10.1016/S0016-5085(00)70443-4
  20. McColl KE, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:239.
  21. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825. https://doi.org/10.1111/j.1572-0241.2007.01393.x
  22. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. https://doi.org/10.1136/gut.2006.101634
  23. Poynter D, Selway SA, Papworth SA, Riches SR. Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut 1986;27:1338-1346. https://doi.org/10.1136/gut.27.11.1338
  24. Safholm C, Havu N, Forssell H, Sundell G, Mattsson H. Effect of 7 years' daily oral administration of omeprazole to beagle dogs. Digestion 1994;55:139-147. https://doi.org/10.1159/000201139
  25. Maton PN. Omeprazole. N Engl J Med 1991;324:965-975. https://doi.org/10.1056/NEJM199104043241406
  26. Bateson MC. Hypergastrinaemia with long-term omeprazole treatment. Aliment Pharmacol Ther 1999;13:440-441.
  27. Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007;52:2482-2489. https://doi.org/10.1007/s10620-006-9419-3
  28. Robinson M. Review article. current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999;13(Suppl 5):5-10.
  29. Larsson H, Carlsson E, Hakanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988;95:1477-1486.
  30. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-669. https://doi.org/10.1016/S0016-5085(00)70135-1
  31. Waldum HL, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. Dig Dis Sci 2005;50(Suppl 1):S39-44.
  32. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006;55:1217-1221. https://doi.org/10.1136/gut.2005.090514
  33. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789. https://doi.org/10.1056/NEJMoa001999
  34. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118:36-47. https://doi.org/10.1016/S0016-5085(00)70412-4
  35. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003;63:942-950.
  36. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011;60:624-630. https://doi.org/10.1136/gut.2010.207662
  37. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37. https://doi.org/10.1038/nrc703
  38. Hirai I, Sasaki T, Kimoto A, Fujimoto S, Moriyama T, Yamamoto Y. Assessment of East Asian-type cagA-positive Helicobacter pylori using stool specimens from asymptomatic healthy Japanese individuals. J Med Microbiol 2009;58:1149-1153. https://doi.org/10.1099/jmm.0.010934-0
  39. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-394. https://doi.org/10.1111/j.1572-0241.2000.01758.x
  40. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-57. https://doi.org/10.1016/S0016-5085(98)70364-6